4.69
-0.18 (-3.7%)
-0.18 (-3.7%)
Upgrade to Real-Time
Afterhours (Closed)
Low
4.5017
High
17.99
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galecto Inc | GLTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.18 | -3.7% | 4.69 | 19:59:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.89 | 4.58 | 5.04 | 4.74 | 4.87 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.67 | 4.71 | 0.04 | - | 1 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,827 | 971,169 | $ 4.75 | $ 4,611,782 | 1,990,026 | 4.5017 - 17.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:55 | 1 | $ 4.69 | USD |
Galecto Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 118.48M | 25.26M | 19.59M | $ - | $ - | -7.86 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 72.00k | 0.20% |
Galecto News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.54 | 6.50 | 4.58 | 5.64 | 5,870,758 | -0.85 | -15.34% |
| 1 Month | 4.99 | 16.41 | 4.5017 | 6.22 | 3,058,828 | -0.30 | -6.01% |
| 3 Months | 6.45 | 16.41 | 4.5017 | 6.19 | 1,028,405 | -1.76 | -27.29% |
| 6 Months | 13.89 | 16.41 | 4.5017 | 6.30 | 491,370 | -9.20 | -66.23% |
| 1 Year | 15.77 | 17.99 | 4.5017 | 6.55 | 393,526 | -11.08 | -70.26% |
| 3 Years | 15.77 | 17.99 | 4.5017 | 6.55 | 393,526 | -11.08 | -70.26% |
| 5 Years | 15.77 | 17.99 | 4.5017 | 6.55 | 393,526 | -11.08 | -70.26% |
Galecto Description
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
